相关实验视频

Updated: Sep 18, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

革新前列腺癌检测:经批准的PSMA-PET成像剂的作用

Ute Hennrich¹, Laurène Wagner², Harun Taş²

¹Service Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Pharmaceuticals (Basel, Switzerland)

|June 27, 2025

概括

经批准的四种前列腺特异性膜抗原正子发射断层扫描 (PSMA-PET) 成像剂改善了前列腺癌的诊断和管理. 这些药物增强了检测,分期和个性化治疗,从而改善了患者的治疗结果.

科学领域:

放射性药物放射性药物放射性药物
在瘤学瘤学.
医疗成像医学成像

背景情况:

前列腺癌的诊断和管理已经通过新型成像剂显著提升.
现在有四种已批准的药物,包括[68Ga]Ga-PSMA-11,[18F]DCFPyL,[18F]PSMA-1007和[18F]rhPSMA-7.3.
这些药物在检测前列腺癌方面提供了更高的灵敏度和准确性.

研究的目的:

为提供已批准的前列腺癌PSMA-PET成像剂的全面概述.
讨论PSMA-PET成像中的比较研究和新兴候选人.
突出这些药物对临床实践和患者治疗结果的影响.

主要方法:

对PSMA-PET剂的化学,制药和药用特性进行审查.
对评估诊断绩效的比较研究进行分析.
确定并讨论其他相关的PSMA-PET候选人.

主要成果:

有四种PSMA-PET药物 (Locametz/Illuccix/Gozellix,Pylarify/Pylclari,Radelumin,Posluma) 已被批准用于前列腺癌成像.
这些药物在检测,分期和管理方面取得了显著的改进.
预计在临床实践中增加使用将改进诊断精度和个性化治疗.

结论:

已批准的PSMA-PET剂代表了前列腺癌治疗的重大进步.
这些药物提高了诊断的准确性,并促进了个性化的治疗策略.
该审查为当前和未来的PSMA-PET成像环境提供了有价值的见解.

关键词:

欧洲药品管理局 (EMA) 的批准.美国食品和药物管理局 (FDA) 批准这就是GozellixTM.伊卢西克斯® (Illuccix®) 是一个非常好的产品.在Locametz®中使用.在PET诊断中使用PET诊断.在PSMA上,PSMA可以在PSMA上进行交易.这就是Posluma®.在Pylarify®中使用Pylarify®.这就是Pylclari®.在Radelumin®®中,您可以使用Radelumin®.-18 -18 -18 -18 -18 -18 -18 -18 -68是一种.前列腺癌是前列腺癌.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...